CA2301157A1 - Conjugates that contain the homeodomain of antennapedia - Google Patents

Conjugates that contain the homeodomain of antennapedia Download PDF

Info

Publication number
CA2301157A1
CA2301157A1 CA002301157A CA2301157A CA2301157A1 CA 2301157 A1 CA2301157 A1 CA 2301157A1 CA 002301157 A CA002301157 A CA 002301157A CA 2301157 A CA2301157 A CA 2301157A CA 2301157 A1 CA2301157 A1 CA 2301157A1
Authority
CA
Canada
Prior art keywords
conjugate
region
protein
cells
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002301157A
Other languages
English (en)
French (fr)
Inventor
Andrea Crisanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trojan Technologies Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2301157A1 publication Critical patent/CA2301157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
  • Medicinal Preparation (AREA)
CA002301157A 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia Abandoned CA2301157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
GB9718609.2 1997-09-02
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Publications (1)

Publication Number Publication Date
CA2301157A1 true CA2301157A1 (en) 1999-03-11

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301157A Abandoned CA2301157A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Country Status (10)

Country Link
US (2) US7968512B2 (enExample)
EP (1) EP1009847A1 (enExample)
JP (1) JP2001514858A (enExample)
AU (1) AU737829B2 (enExample)
BR (1) BR9811744A (enExample)
CA (1) CA2301157A1 (enExample)
GB (1) GB9718609D0 (enExample)
IL (2) IL134602A0 (enExample)
NZ (1) NZ503007A (enExample)
WO (1) WO1999011809A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910554B2 (en) 2001-04-12 2011-03-22 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
WO2017177178A1 (en) 2016-04-07 2017-10-12 Case Western Reserve University Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
WO2019014342A1 (en) 2017-07-11 2019-01-17 Case Western Reserve University COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES
EP3446699A1 (en) 2012-04-09 2019-02-27 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273192A1 (en) * 1996-12-02 1998-06-11 Wake Forest University Inactivation of hiv co-receptors as therapy for hiv infection
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
EP1140202A1 (en) 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
WO2002020737A2 (en) * 2000-09-07 2002-03-14 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
WO2002098365A2 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
AU2010238346A1 (en) 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012154684A2 (en) * 2011-05-06 2012-11-15 University Of Rochester Method of preventing development of psoriatic lesions
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
RU2708375C2 (ru) 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910554B2 (en) 2001-04-12 2011-03-22 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
EP3446699A1 (en) 2012-04-09 2019-02-27 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
EP4285919A1 (en) 2012-04-09 2023-12-06 Case Western Reserve University Compositions for treating neural injury by inhibiting the activity of lar family phosphatases
WO2017177178A1 (en) 2016-04-07 2017-10-12 Case Western Reserve University Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
WO2019014342A1 (en) 2017-07-11 2019-01-17 Case Western Reserve University COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES

Also Published As

Publication number Publication date
NZ503007A (en) 2000-11-24
IL134602A0 (en) 2001-04-30
JP2001514858A (ja) 2001-09-18
US20080317773A1 (en) 2008-12-25
US7968512B2 (en) 2011-06-28
US8735340B2 (en) 2014-05-27
AU737829B2 (en) 2001-08-30
BR9811744A (pt) 2002-01-02
GB9718609D0 (en) 1997-11-05
IL134602A (en) 2006-10-31
US20110256168A1 (en) 2011-10-20
WO1999011809A1 (en) 1999-03-11
AU8877698A (en) 1999-03-22
EP1009847A1 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
AU737829B2 (en) Conjugates that contain the homeodomain of antennapedia
US10947539B2 (en) Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
US20080039397A1 (en) Tropoelastin derivatives
JPH09511916A (ja) 核酸伝達系
JP2000503856A (ja) Ｂｐｉ融合タンパク質及びｂｐｉ由来ペプチドの微生物での組換え製造のための方法
JP2022542294A5 (enExample)
KR20220007619A (ko) 면역조절 조성물 및 방법
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
KR101651330B1 (ko) 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도
KR101106262B1 (ko) 인간 호메오 도메인 유전자 유래의 단백질 도입 도메인 및 이를 이용한 단백질 도입 벡터
KR20240004247A (ko) 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2
WO2001040463A1 (fr) Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique
CN101104856B (zh) 一个系列的非病毒载体及包含其的药物组合物
KR20120035566A (ko) 세포 투과성 ｒｐＳ3 융합 단백질을 포함하는 신경질환 예방 및 치료용 약학 조성물
CA2391881A1 (en) Transfer compounds, production and use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140603